1203-47-0

Usage

Uses

Used in Pharmaceutical Industry:
2,3,8-Trimethylquinolin-4-ol is used as an intermediate in the synthesis of various drugs, leveraging its potential anti-cancer and anti-microbial properties. Its ability to target and inhibit specific biological pathways makes it a promising candidate for the development of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 2,3,8-Trimethylquinolin-4-ol serves as an intermediate in the production of pesticides, capitalizing on its anti-microbial properties to protect crops from harmful pathogens and enhance agricultural productivity.
Used in Medicinal Research:
2,3,8-Trimethylquinolin-4-ol is utilized as a subject of research for its potential anti-cancer properties, with studies exploring its ability to modulate oncological signaling pathways and exert inhibitory effects on tumor growth and progression.
Used in Healthcare Industry:
TMQ-4-ol is employed for its antioxidant and anti-inflammatory properties, making it a valuable component in the development of health supplements and therapeutic formulations aimed at promoting overall well-being and combating inflammation-related disorders.
Used in Cosmetic Industry:
In the cosmetic sector, 2,3,8-Trimethylquinolin-4-ol is used for its antioxidant properties, which can help protect the skin from oxidative stress and promote a youthful appearance. Its anti-inflammatory effects also contribute to the development of skincare products designed to soothe and calm irritated skin.

Upstream product

• 95-53-4 o-toluidine 
• 609-14-3 2-acetylpropanoic acid ethyl ester 

Downstream Products

• 915722-79-1 N-(3-methylaminopropyl)-N'-(2,3,8-trimethylquinolin-4-yl)benzene-1,4-diamine 
• 1203-45-8 4-chloro-2,3,8-trimethylquinoline 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Structure-activity relationship of quinoline derivatives as potent and selective α2c-adrenoceptor antagonists

Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human α2- adrenoceptor subtypes (α2A, α2B, and α2C). A number of compounds with good antagonist potencies against the α2C-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl)phenylamino]quinolin-3-yl}methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the α2c-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the α2C- adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.